Kidney Transplant Recipients
36
7
7
16
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 39/100
11.1%
4 terminated out of 36 trials
80.0%
-6.6% vs benchmark
42%
15 trials in Phase 3/4
44%
7 of 16 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 16 completed trials
Clinical Trials (36)
Prediction and Prevention of Bloodstream Infections After Kidney Transplantation
Efficacy, Mechanisms and Safety of SGLT2 Inhibitors in Kidney Transplant Recipients
Eduction in ImmunoSuppressive Regimen Among Kidney Transplant Recipients Patients Admitted to the Intensive Care Unit for Septic Shock and/or Acute Respiratory Failure
Neurocognitive Function Changes With Extended-Release Tacrolimus Among Older Kidney Transplant Recipients
The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients
Role of Epoxyeicosatrienoic Acids in Chronic Allograft Nephropathy - The TRANSPLANT-EETs Study
COVID Protection After Transplant-Immunosuppression Reduction
Diode Laser-Assisted Periodontal Therapy in Kidney Transplant Recipients
Pilot Trial of Supplemental Vitamin A and Nicotinamide
Velocity-Based Resistance Training in Kidney Transplant Recipients
Paired Marrow Aspirations to Assess Assays in Sensitized Renal Allograft Recipients
Envarsus XR Compared to Immediate Release Tacrolimus
Immunological Follow-up After SARS CoV2 Vaccination in Kidney Transplant Recipients
COVID-19 Protection After Transplant Pilot Study
The Effects of Physical Activity Behavior Change in Kidney Transplant Recipients
Exercise and Diet Effects in Reducing Cardiovascular Risk in Kidney Transplant Recipients
A Study to Evaluate the Efficacy and Safety in Kidney Transplant Recipients When Changed From Cyclosporine to Tacrolimus Prolonged-release Capsule or Tacrolimus Capsule
Observational Study to Evaluate the Safety and Efficacy of ATG-F on Kidney Transplant Recipients
Treg Modulation With CD28 and IL-6 Receptor Antagonists
Risk Factors of Chinese Kidney Transplant Recipients DSA Based on MPA Immunosuppressive Regimen